Janux Therapeutics (JANX) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.34

Estimate

-$0.49

Surprise

+30.4%

Revenue (period 2026-09-30)

$9.3M

Score today

4.5/10

Revenue source: xbrl.

Janux Therapeutics (JANX) reported a narrower loss than forecast — adjusted EPS of -$0.34 against the -$0.49 estimate (a 30.4% beat on a still-unprofitable quarter).

• Barclays and Wedbush Update Price Targets for Janux Therapeutics — fiscal.ai, 2026-11-06
• Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27 — benzinga, 2026-11-06
• Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40 — benzinga, 2026-11-06

TrendMatrix currently rates JANX Sell at 4.5/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +30.4% surprise compares with a +13.7% four-quarter average. Next scheduled report: 2027-02-25.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$17.63

Price target

$28.86

Stop

$16.40

Upside to target

+63.7%

Reward-to-risk

5.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-07 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.08B

P/E (fwd)

-6.7

52-week range

$12.12–$35.34

Off 52-week high

50.1%

RSI (14)

56

Volume vs avg

1.20×

Score today

4.5/10